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S U M M A R Y
Objectives: Rotavirus is the most important etiology of severe diarrhea in Bolivia. The monovalent
attenuated human oral rotavirus vaccine Rotarix1 was introduced in Bolivia in 2008. We describe the
molecular epidemiology of circulating rotavirus strains before vaccine introduction.
Methods: Two thousand one hundred thirty-ﬁve diarrheal samples were collected from hospitals in four
Bolivian cities during 2007–2008. Forty-three percent (445 of 1030 rotavirus-positive samples) were
analyzed for G and P genotypes. Among those, 331 were electropherotyped by polyacrylamide gel
electrophoresis. Disease severity was quantiﬁed using a modiﬁed Vesikari scale.
Results: Among the 445 samples, ﬁve genotypes were found to be prevalent: G9P[8] (33%), G1P[6] (17%),
G2P[4] (13%), G9P[6] (12%), and G1P[8] (4%). Co-infections with two or more strains accounted for 14% of
samples. The most prevalent strain, G9, showed greater electropherotype diversity compared to other
serogroups. Strain G1P[6] generally infected younger children and peaked later in the year than other
strains. No particular genotype was associated with a higher severity score, though there was a
signiﬁcant difference in the duration of diarrhea between genotypes.
Conclusions: During the 2-year pre-vaccine period, substantial diversity of rotavirus co-circulating
strains was observed. These data constitute a baseline against which changes in circulating strains post-
vaccine introduction can be monitored.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Rotavirus is the leading cause of severe acute gastroenteritis in
infants and young children worldwide.1 In the pre-rotavirus
vaccine era, nearly every child was infected with rotavirus before
the age of ﬁve, and more than 85% of the mortality burden due to
rotavirus occurred in the developing world, as poor access to
medical care, malnutrition, and coexisting infections are frequent
complicating factors.2
Among group A rotaviruses, two subgroups (I and II) can be
found based on the reactivity of the VP6 protein. Two surface
antigens to which neutralizing antibodies attach, known as VP7
(designated G) and VP4 (designated P), are used to further classify
rotaviruses according to their serotype and genotype.3 Ten G* Corresponding author. Tel.: +1 591 2261 28 15; fax: +1 591 2279 75 11.
E-mail address: volgavir@yahoo.com (V. In˜iguez).
1 They contributed equally to the development of this manuscript.
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http://dx.doi.org/10.1016/j.ijid.2013.03.016serotypes and 11 P genotypes have been identiﬁed in humans.4 An
additional method for distinguishing rotavirus strains is electro-
pherotyping, in which migration patterns of 11 double-stranded
(ds) RNA segments are compared between virus isolates.5
The clinical presentation of rotavirus encompasses a wide range
of severity of symptoms, from asymptomatic infection to severe
dehydrating diarrhea.6 Little clear evidence has emerged regarding
the host or viral factors that contribute to severe disease. Several
studies have investigated associations between infection with
rotavirus G types and P types and illness severity, but have not
found any consistent patterns in terms of the particular genotypes
associated with severe disease.6–10
A review of the epidemiology of rotavirus in Latin America pre-
rotavirus vaccine revealed a need for consistent and comprehen-
sive rotavirus surveillance by countries in the region, as the
availability of long-term data was limited.11 In South America,
studies published between 1989 and 2004 found that the most
common rotavirus genotypes included G1P[8] (34%), G2P[4] (23%),
G9P[8] (15%), and G4P[8] (9%).4ses. Published by Elsevier Ltd. All rights reserved.
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that the rotavirus vaccine be incorporated into routine immuniza-
tion programs of all countries.12 Results of rotavirus vaccine trials
have shown that vaccine effectiveness is lower in developing
countries than in developed countries.13–17 The reasons for this
disparity are not entirely clear, but understanding some of the
factors that lead to disease severity in the absence of a vaccine may
help provide insight into why vaccines are less effective in these
settings.
Although the rotavirus vaccines are highly effective at
preventing hospitalizations due to rotavirus diarrhea, they do
not prevent rotavirus disease altogether. Thus, it will be important
to monitor the vaccine’s effects on rotavirus strain diversity in the
years following its introduction.
In Bolivia, acute diarrheal diseases represent a major public
health problem and are the leading cause of the high morbidity and
mortality rates in young children.18 Bolivia introduced the
rotavirus vaccine into its routine immunization schedule in August
of 2008. The goal of this study was to describe the molecular
epidemiology of rotavirus in Bolivia prior to the introduction of the
rotavirus vaccine and to identify some of the viral factors that may
contribute to disease severity.
2. Materials and methods
2.1. Study sites and study population
The study took place from January 2007 to December 2008 in
ﬁve tertiary hospitals of four Bolivian cities covering the major
geographic regions of Bolivia: highlands (Hospital Materno-
Infantil and Hospital Del Nin˜o in La Paz, Hospital Boliviano
Holande´s in El Alto), valleys (Hospital Albina Patin˜o in Cocha-
bamba), and tropical lowlands (Hospital Mario Ortiz in Santa Cruz).
Surveillance took place among children 0–59 months of age
admitted to the hospitals as inpatients with a diagnosis of acute
diarrhea. Diarrhea was diagnosed according to the WHO deﬁnition
of three or more watery stools in 24 h. Data were collected on all
children with a diagnosis of diarrhea. Those who had persistent
diarrhea upon hospitalization or had a nosocomial diarrhea were
excluded. Over the surveillance period, a total of 2135 samples
were collected and laboratory tested for rotavirus; 849 samples
were collected from the cities of La Paz and El Alto, 883 from
Cochabamba, and 403 from Santa Cruz. The surveillance system
was able to access approximately 87% of all fecal specimens from
children identiﬁed as acute diarrheal cases.
2.2. Sample collection
Within 48 h after hospitalization, at least 5 ml of stool was
directly collected and stored in a plastic vial or in the diaper.
Samples were kept at 4 8C until they were transported to the
laboratory at the Universidad Mayor de San Andre´s where they
were stored at 20 8C prior to analysis.
Clinical information was extracted from the medical chart of
each child. Information included the child’s sex, age at admission,
symptoms, hydration status, height, weight, and length of hospital
stay.
2.3. Rotavirus detection and strain characterization
Rotavirus status was ascertained by ELISA (IDEIA-Dako). G and
P genotyping was performed by reverse transcription (RT)-PCR on
43% of randomly selected rotavirus-positive samples. Rotavirus
RNA was extracted in accordance with previously described
methods for nucleic acid puriﬁcation.19 The extracted RNA was
used for RT-PCR as described to ascertain G, P, and VP6genotypes.20–22 Amplicons were analyzed on a 1.5% Tris–
borate–EDTA (TBE) agarose gel and viewed under ultraviolet
illumination after ethidium bromide staining.
2.4. Electropherotyping
Electropherotyping of viral RNA was available for 331 samples,
using 7% polyacrylamide gels.23 Long and short migration ds
rotavirus RNA patterns were categorized as L and S respectively
based on co-migration differences.20,24
2.5. Data entry and analysis
All data were collected by surveillance program staff and
entered into Epi Info version 3.5.1 (CDC, Atlanta, GA, USA). Data
were imported into and analyzed in SAS v 9.2 (SAS, Cary, NC, USA).
2.6. Evaluation of disease severity
A modiﬁed version of the previously described Vesikari scale
was used to determine clinical severity of diarrhea episodes.6 The
following three modiﬁcations were made. A 17-point scale was
used in lieu of a 20-point scale, as information on the duration of
vomiting was not available. The original Vesikari scale categorizes
dehydration according to the percentage of body weight lost.
Because the surveillance program did not classify dehydration this
way, we used the program’s four-level scale categorized by the
following: no dehydration, moderate dehydration, severe dehy-
dration, and shock. The maximum number of vomiting episodes in
24 h was modiﬁed to the number of vomiting episodes in the 24 h
preceding hospitalization, as the number of vomiting episodes was
not recorded daily; the same was true for the number of diarrheal
depositions.
2.7. Statistical analysis
Normality was assessed for all continuous variables. Several
continuous variables, including age, duration of diarrhea, number
of vomiting episodes in 24 h, and the number of diarrheal
depositions did not follow a normal distribution. For these
variables a log10 transformation was used, which resulted in a
normal distribution. For all statistical analyses, a p-value of less
than 0.05 was considered statistically signiﬁcant. Analysis of
variance (ANOVA) and Tukey pairwise comparisons were used to
compare the severity score, duration of diarrhea, number of
depositions, number of vomiting episodes, and age at infection
among rotavirus genotypes. The Chi-square test and Fisher’s exact
test were used to make comparisons among categorical variables.
3. Results
3.1. Rotavirus strain dynamics in Bolivia
In order to investigate the dynamics of circulating strains of
rotavirus, we analyzed rotavirus genotype data in association with
demographic and temporal characteristics. 2135 diarrheal samples
were collected from ﬁve hospitals in four Bolivian cities between
January 2007 and December 2008. Four hundred forty-ﬁve (43%) of
the 1030 rotavirus-positive samples were analyzed for G serotype
and P genotype. Five strains representing common G–P types
predominated (78%) during the study period: G9P[8] (33%), G1P[6]
(17%), G2P[4] (13%), G9P[6] (12%), and G1P[8] (4%). We found that
the strain proportions of G9P[8] and G9P[6] were consistent across
the years, while the strain proportions of G1P[6], G1P[8], and
G2P[4] varied from year to year (Figure 1). Speciﬁcally, G2P[4]
exhibited considerable variation between years, ranging from 3% in
Figure 1. Genotype distribution 2007–2008. Five genotypes predominated during the surveillance period, and G1P[6], G1P[8], and G2P[4] showed considerable variation by
year.
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The majority of the mixed infections (92%) were associated with G9
and G1 strains (data not shown). Unconventional G and P
associations, particularly G9 with P[4], or uncommon rotavirus
genotypes, such as G4P[6], were observed infrequently (<1% of
cases).
The strain proportions of all ﬁve strains were quite distinct
across cities (data not shown). The distribution of rotavirus
genotypes showed variation by season (Figure 2). The incidence of
three strains, G1P[8], G2P[4], and G9P[8], all peaked at the same
time coinciding with the primary peak of rotavirus from April to
July, and then decreased to low levels. Interestingly, the majority of
cases of G1P[6] were found later in the year, from August to
October, with low levels of infection during the primary rotavirus
peak from April to July and higher levels during the secondary peak
between August and October. G9P[6] had two peaks, one at the
latter end of the primary rotavirus peak and a second in September
during the secondary rotavirus peak. The same patterns were
observed when looking at data from each year individually (data
not shown) as when examining aggregated data. In summary, ﬁve
genotypes predominate in Bolivia, showing variation across cities
and seasons.
3.2. Genotype and severity
In order to investigate the relationship between the rotavirus
strain and disease severity in this population, we used clinical data
to calculate the Vesikari score quantifying disease severity. ClinicalFigure 2. Two genotypes, G1P[6] and G9P[6], had peaks outside the primary
rotavirus peak (April to July). Lines represent the number of cases per month
(month 1 = January, 2 = February, etc.) for each genotype as a percentage of the total
number for that genotype for the period 2007–2008.data were not complete for all observations. Of 2135 observations,
only 516 included all of the required clinical information for a
calculable severity score; 228 of these were rotavirus-positive. Of
the 228 rotavirus-positive cases with calculable Vesikari scores, 83
had genotype data. We found no differences in the mean severity
score among the ﬁve most common genotypes (Table 1). Scores
ranged from 10 to 16 and the median score was 13. In addition to
the overall severity score, we examined each of the clinical
symptoms individually for associations with genotype. The
duration of diarrhea showed signiﬁcant differences by genotype
(Table 1) and there were no signiﬁcant differences in strain
distribution by gender (data not shown). Additionally, children
infected with the G1P[6] strain were of a signiﬁcantly lower
average age at the time of infection than children infected with the
G1P[8], G2P[4], and G9P[8] strains (Table 1). In addition we
performed separate analyses looking at associations between
severity and G type and P type discretely. No signiﬁcant differences
were found between G types or P types for overall severity score
(data not shown). These data suggest that in Bolivia, in general, all
common strains of rotavirus are equally severe, and thus it is
important that vaccines show high efﬁcacy and effectiveness
against all of these strains.
3.3. Electropherotype diversity
Fourteen electropherotypes were identiﬁed between 2007 and
2008 by examination of RNA migration patterns in polyacrylamide
gels. Strains with long electropherotypes (L) were predominant
(85%) and showed more variation (12 discrete variants), while
short electropherotypes (S) were less frequent (15%) and showed
only two variants (S1 and S2). Electropherotypes showed
considerable temporal diversity. Electropherotypes S1 and variant
forms of L3 (L3-1, L3-2) were somewhat rare in 2007, accounting
for approximately 25% of the total electropherotypes identiﬁed in
that year, while in 2008 those three electropherotypes emerged to
be predominant, accounting for almost 85% of total electropher-
otypes in that year (Table 2). Conversely L1 and L5 were relatively
common in 2007 (39%) but virtually disappeared in 2008 (2%).
Strains with electropherotypes L1, L3, and L5 were dominant in
2007, and electropherotypes L3-1, L3-2, and S1 were dominant in
2008 (Table 2). Co-circulation of more than one type was observed
annually, particularly during the peak months of rotavirus
infection where the highest frequency of co-infections was
recorded.
Some genotypes were frequently associated with a particular
electropherotype. G2P[4], as part of the DS-1-like genogroup, was
almost exclusively found in conjunction with electropherotype S,
G1P[8] was always observed with the L5 electropherotype
Table 1
Associations between genotypes, disease severity and clinical characteristics
G1P[6]
Mean  SD, column %
(n = 75)
G1P[8]
Mean  SD, column %
(n = 16)
G2P[4]
Mean  SD, column %
(n = 59)
G9P[6]
Mean  SD, column %
(n = 54)
G9P[8]
Mean  SD, column %
(n = 145)
Total Na
Average age at infection (months) 8.0  6.9 12.8  5.6b 11.8  5.4b 9.5  6.2 11.4  5.7b 349
Modiﬁed Vesikari score 13.5  1.5 13.0  1.4 12.7  1.2 13.8  1.5 13.7  1.5 83
Duration of diarrhea 7.1  4.1c 6.3  3.3 5.4  2.8 7.8  2.9c 7.1  3.4c 254
Number of depositions 8.2  3.5 7.2  2.9 7.1  3.1 7.4  3.2 8.2  4.1 347
Number of vomiting episodes 5.6  3.6 4.5  2.7 5.4  4.1 4.6  2.7 5.3  3.0 309
Incidence of vomiting (%) 92 94 93 93 94 349
Hydration status (%)
None 2.7 0 1.7 1.9 2.1 7
Moderate 64 62.5 74.6 48.2 68.3 227
Severe 32 37.5 22 48.2 28.3 110
Shock 1.3 0 1.7 1.9 1.4 5
Metabolic acidosis (%) 79 100 81 83 76 163
a Sample size varies by category, based on available clinical information.
b p < 0.05 compared to G1P[6].
c p < 0.05 compared to G2P[4].
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diversity of long electropherotypes.
3.4. Association between VP6 subgroup genotypes and
electropherotypes
In addition to the VP6 genogroup determined by RT-PCR, the G
types, P types, and electropherotypes of the rotavirus strains were
determined, and the associations between genogroups, genotypes,
and electropherotypes were analyzed. We found that G2P[4]
strains were mostly associated with subgroup I (83%) and with
short electropherotypes (100%), while non-G2P[4] genotypes
(G9P[8], G1P[6], G9P[6]) were associated with subgroup II (98%)
and with long electropherotypes (100%). A number of strains with
unusual associations were identiﬁed, such as G2P[4] sgII S, G9P[4]
sgI L, G4P[6] sgI L, G2P[6] sgII L, G4P[6] sgII L, and G9P[8] sgI-II L.
The unusual combination of G2P[4] with subgroup II and short
electropherotypes (17%), suggests the occurrence of inter-gen-
ogroup reassortment.
4. Discussion
The goal of this study was to describe the molecular
epidemiology of rotavirus in Bolivia prior to the introduction of
the rotavirus vaccine and to identify viral factors that may
contribute to the severity of rotavirus illness. The present study
conﬁrms that, in the same country, in different regions, and from
year to year, circulating rotavirus genotypes and electropherotypes
may be highly variable. Five rotavirus genotypes predominated,
accounting for 99% of the total genotyped samples. Considerable
electropherotype diversity was observed, with 14 distinct RNA
migration patterns detected. Genotypes G1P[6], G1P[8], andTable 2
Electropherotype counts during peak rotavirus periods
2007 
April May June July August Total (%) 
S1 1 2 3 0 0 6 (3.5) 
L1 7 20 11 1 1 40 (23.1) 
L2 1 4 3 1 13 22 (12.7) 
L3 5 13 21 1 0 40 (23.1) 
L3-1 7 10 3 1 5 26 (15.0) 
L3-2 4 5 3 0 0 12 (6.9) 
L5 3 15 7 0 2 27 (15.6) 
Total 28 69 51 4 21 173 (100) 
a Electropherotype data not available for August 2008.G2P[4] showed little electropherotype diversity, associating
overwhelmingly with one particular electropherotype, while
genotypes G9P[6] and G9P[8] showed greater electropherotype
diversity, associating consistently and concurrently with several
electropherotypes. No particular genotype was clearly associated
with more severe disease.
Although mixed infections between different G and P genotypes
and different electropherotypes were observed, they were
commonly associated with the most prevalent genotypes and
electropherotypes co-circulating at the time of the study,
providing opportunity for potential reassortment events.
Of the ﬁve most common strains worldwide, three are among
Bolivia’s ﬁve most common (G1P[8], G2P[4], and G9P[8]). A
summary of worldwide rotavirus surveillance data for 1973–2003
indicated that circulating strains showed considerable variation by
region and by year.4 In the South American region, G1 was the most
common serotype, accounting for 57.5% of infections, followed by
G2 (18.3%), G4 (8.8%), and G9 (8.5%).4 In our study, G9 (47.7%) was
the predominant serotype, followed by G1 (32.5%) and G2 (19.4%).
G9 has been an important emerging serotype in the past two
decades,4 and our study conﬁrms the importance of G9 for the
under-ﬁve population in Bolivia. Interestingly, since 2006, the
prevalence of G9P[8] and G9P[6] has been increasing, while G1P[8]
has been decreasing. In contrast, other studies in Ecuador
documented a decrease in G9 from 2005 to 2008 showing that
this genotype was replaced by the G1 and G2 types.25 Similarly,
G1P[8] genotype was considered one of the most prevalent
genotypes worldwide.26,27 Together, these data suggest country-
speciﬁc rotavirus genotype changes each year.
Signiﬁcant year-to-year variations in strain circulation appear
to be common globally.28 For example, an Argentinean study from
2006 revealed an increase in the frequency of G9, while G1 was2008
April May June July Augusta Total (%)
15 16 9 1 41 (25.9)
0 0 0 0 0 (0)
5 2 2 8 17 (10.8)
3 0 0 1 4 (2.5)
16 4 4 1 25 (15.8)
19 27 18 4 68 (43.0)
2 0 0 1 3 (1.9)
60 49 33 16 158 (100)
Figure 3. G9P[6] and G9P[8] showed greater electropherotype diversity than other
genotypes. Bars represent individual electropherotypes as a percentage of the total
electropherotypes detected for each genotype (i.e., total bars for each genotype
should add up to 100).
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from 2004, where G1 accounted for 40% of circulating strains.28 In
Bolivia, the G2P[4] strain increased in frequency in 2008, indicating
a cyclic pattern for this strain (Figure 1). In 2006, G2P[4] accounted
for 23% of total genotyped strains (data not shown), while in 2007
it decreased considerably, accounting for only 4% of the total. In
2008 it reappeared as an important strain, accounting for 26% of
the total. We found that G2P[4] was strongly associated with
subgroup I, while the remaining non G2P[4] genotypes (G1P[6],
G1P[8], G9P[6], and G9P[8]) were associated with subgroup II. This
result is in agreement with other studies that found that subgroups
segregate according to the P type (P[4] associated with sgI and P[8]
with sgII).30 In this study we found unusual G2P[4] strains
associated with sgII and short electropherotypes; this result
suggests that upon mixed infections, P[4] and VP6-encoding genes
can segregate independently in reassorted strains. Reassortment is
considered an important evolutionary mechanism among preva-
lent circulating rotavirus strains.31
The changing rotavirus RNA electropherotype dynamics
observed from year to year in our study were similar to results
that have been demonstrated elsewhere in the world.5 During each
seasonal peak of rotavirus, several rotavirus RNA electropher-
otypes circulated, with a few high frequency strains predominat-
ing, and several less common strains exhibiting lower levels of
activity (Table 2). The rotavirus strains occurred in a periodic
manner in which some strains disappeared and were replaced by
new strains. It was also shown that, whereas some strains
circulated for short periods (L1, L3), other persisted for longer
periods of time (L2, L3-1, Table 2). Two groups of RNA patterns
were detected, designated long and short proﬁles. The predomi-
nant electrophoretic pattern detected in children from Bolivia was
the long electropherotype (85%), which has more variation in
comparison to the short pattern. The predominance of the long
electropherotype appears to be common globally.32,33 The short
patterns showed less diversity and a cyclic pattern of emergence,
therefore we hypothesize that these strains are undergoing
antigenic drift, as this would explain their distribution in time
and the reduced accumulation of mutations. It is interesting to
note that strains G9P[6] and G9P[8], the two most prevalent strains
throughout the study period, showed greater electropherotype
diversity than other strains (Figure 3). We also hypothesize that
their success and growth over time can be partially attributed to
this diversity.
Few studies have found differences in strain distribution by age
group. To our knowledge, this is the ﬁrst study to suggest that
G1P[6] infects younger children (Table 2). An Italian study foundthat G2P[4] infected older children;34 in our study G2P[4] had the
highest mean age at infection, but was not itself signiﬁcantly
different from any genotype other than G1P[6] (Table 2). The
Italian authors hypothesized that the higher mean age for G2
infections was attributable to the fact that the G2 infections may
have been re-infections of children previously infected with
another rotavirus genotype. However, this hypothesis would not
serve to explain our ﬁnding of a signiﬁcantly younger mean age for
G1P[6]. Maternal antibodies against rotavirus are thought to
provide protection to young infants against rotavirus infection.27
G1P[6] is an uncommon genotype globally, and perhaps maternal
antibodies to this genotype are less common. G1P[6] was also
anomalous in that it peaked later in the season than other
genotypes (Figure 2). A study in Colombia found that the three
most common strains (G1P[8], G2P[4], and G3P[8]) showed
distinct seasonal patterns that were consistent across all three
cities studied in spite of different climatological factors.35 In our
study, G1P[6] and G9P[6] showed consistently later peaks, and the
pattern was consistent over both years of surveillance. Though the
reason for this is not clear, one hypothesis that we might propose is
that these two strains are less infective in our population than
other strains and thus cannot compete efﬁciently during the
rotavirus peak when other strains show high circulation.
Our study did not identify an association between genotype and
overall disease severity (Table 1). Numerous studies have
examined severity in relation to virus type, but no consistent
patterns have emerged. One study that came out of the placebo
arm of a Latin American vaccine trial found that G9 caused more
severe disease in comparison to G1 (a more common serotype
globally).7 Despite a relatively small sample size (n = 45), they
found that G9 had a higher severity score, longer duration of
diarrhea, more frequent hospitalization, and more severe dehy-
dration as compared to G1.7 In contrast, a study among French
children hospitalized for rotavirus found no difference in severity,
length of hospitalization, or the necessity for intravenous
rehydration between G1 and G9 strains.9 A third study of
hospitalized rotavirus patients in India found that G1 caused
more severe disease and more severe dehydration than G9 strains.8
Several theories have been put forward to explain these incon-
sistencies. One plausible suggestion is that strains newly intro-
duced into a community may cause more severe disease due to the
lack of pre-existing immunity.7 Also, there may be year-to-year
variations in virulence of particular serotypes or genotypes.8
This study demonstrates the importance of rotavirus as an
agent of severe diarrhea in Bolivia, and did not identify a strong
association between rotavirus strain and severity of disease,
emphasizing the importance that the vaccine is effective against all
rotavirus genotypes.
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